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ABSTRACT
Background
Cyanoacrylates (CA) are fast-acting strong adhesives used in a variety of applications in
procedural medicine including closure of superficial wounds, embolisation of truncal
vessels pre-operatively, vascular anomalies, visceral false aneurysms, endoleaks,
gastrointestinal varices and gastrointestinal bleeding. More recently, catheter-directed
Cyanoacrylate Adhesive Closure (CAC) was introduced as an alternative to endovenous
thermal ablation (ETA) to occlude superficial veins of the lower limbs.
Objectives
To formulate policies for the safe and effective delivery of CAC procedures in Australasia,
based on current experience and evidence.
Methods
A panel of phlebologists including vascular surgeons, interventional radiologists,
dermatologists and research scientists systematically reviewed the available data on CA
products used in medicine and shared personal experience with the procedure. The
reviewed material included bibliographic and biomedical data, material safety data sheets
and data requested and received from manufacturers.
Results and Recommendations
CAC appears to be an effective treatment for saphenous reflux with occlusion rates at 36
months of 90-95%. We recommend a maximum dose of 10mL of CA per treatment
session. Serious complications are rare, but significant. Hypersensitivity to acrylates is
reported in 2.4% of the population and is an important absolute contraindication to CAC. 1

4

Post procedural inflammatory reactions, including hypersensitivity-type phlebitis (HTP),
occur in 10-20% of patients. In the long-term, CAC results in foreign-body granuloma
formation within 2-12 months of the procedure. We recommend against the use of CAC
in patients with uncontrolled inflammatory, autoimmune or granulomatous disorders (e.g.
sarcoidosis). Caution should be exercised in patients with significant active systemic
disease or infection and in these patients alternative therapies such as thermal ablation
and foam sclerotherapy should be considered.
Conclusions
CAC appears to be an effective endovenous procedure, with short term closure rates
comparable to ETA and therefore greater efficacy than traditional surgery for treating
superficial veins of the lower limbs. Ongoing data collection is required to establish the
long-term safety and in particular, the risks associated with immune-mediated or foreign
body type reactions.
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INTRODUCTION
Cyanoacrylate (CA) adhesives were first patented in 1949 and are well-known fast-acting
strong adhesives commonly used for domestic and industrial purposes under brand
names such as “Super Glue”. These adhesives are administered as liquid monomers that
polymerise on contact with free radicals and anions such as those found in water with
variable flexibility depending on constituents.
CA differ depending on the length of the carbonyl group of the molecule. N-butyl
cyanoacrylate (n-BCA) is the most common adhesive used in medicine and was
introduced in the late 1960s for closure of minimum tension wounds and as a substitute
for suturing2. Since then, the regulatory authorities including the United States (USA)
Food and Drug Administration (FDA) have granted approval for a range of products and
several medical indications.3,

4

Histoacryl® was the first medical grade adhesive

introduced in 1968. The Trufill® preparation was approved by the FDA for treating cerebral
arteriovenous malformations (AVMs) in 2000.5 In 2012, VenaSealTM was registered in
Australia as the first n-BCA designed for peripheral venous interventions providing a nonthermal alternative to endovenous thermal ablation (ETA) of the great (GSV) and small
saphenous veins (SSV). Since then, other similar products such as VenaBlock TM have
gained registration in Australia. In all cases the CA products have been approved by the
Australian Therapeutic Goods Administration (TGA) as medical devices and not as drugs
for use in humans. This means there is no safety data, phase 1 safety trials or TGA
approved Prescriber Information (PI) for their use in a clinical setting. In addition,
clinicians have used the drug without full disclosure of its constituent ingredients and in
particular the additives and solvents used, which may be associated with immunemediated reactions.
6

Given the popularity of endovenous procedures, standardisation of techniques and cross
specialty procedural training have become necessary. The Australasian College of
Phlebology (ACP) has previously released training and procedural standards for other
endovenous procedures including endovenous laser ablation (EVLA) and ultrasoundguided sclerotherapy (UGS).6 The current document reviews the clinical applications of
cyanoacrylate closure (CAC) for lower limb veins in Australasia. We outline the relevant
protocols for the assessment, treatment and post-treatment follow-up of superficial
venous disease management using CAC.
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METHODS
Literature Search and Data Collection
The published scientific, biomedical and regulatory literature was reviewed including
MEDLINE and EMBASE, journal articles, product information sheets, material safety data
sheets, Australian TGA, Australian Register of Therapeutic Goods (ARTG), National
Institute for Health and Excellence (NICE) interventional procedural guidelines and
National Industrial Chemical Notification and Assessment Organization [16 December
2018]. Manufacturers of VenaBlockTM and VenaSealTM, Invamed and Medtronic
respectively, were contacted to provide information on the physiochemical, safety and
regulatory data of each product through a standard set of questions (Appendix 1).
Panel Members
The document was written by the primary authors (KP, SR, MK). A panel from Australia
and New Zealand was invited to review the paper and make evidence-based
recommendations. This occurred via an initial face-to-face meeting followed by digital
communication. The panel had 22 members which included phlebologists, endovascular
surgeons,

interventional

radiologists,

dermatologists,

research

scientists

and

independent research fellows. The clinician members of the panel all had experience in
using CA and significant personal experience in endovenous thermal and non-thermal
ablation. None of the panel members had a current conflict of interest to declare. One
panel member had served as consultant for Medtronic previously.
Terminology and Abbreviations
Abbreviations used in the current document are summarised in Table 1.
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1.

PRODUCT REVIEW

Preparations containing medical grade CA have been used as venous occlusive agents,
embolic agents and for closure of minimum tension superficial wounds. In this paper, we
focus on the use of medical grade CA as occlusive agents to treat peripheral veins and
review their established use as embolic and adhesive agents. All products discussed here
are n-BCA with the exception of Dermabond® which is an octyl-CA and Onyx® which is
not a CA. We also briefly review the use of other acrylates as adhesives in wound
dressings. Technical considerations are discussed under Section 5.
1.1

Occlusive agents to treat peripheral veins

1.2

Embolic agents to treat vascular anomalies

1.3

Adhesive agents for closure of superficial wounds

1.4

Adhesive agents in dressing and bandages

1.1

Cyanoacrylates as Venous Occlusive Agents

Several CAC systems for treatment of peripheral veins are available but only three
products, VenaSealTM, VenaBlockTM and VeinoffTM are registered in Australia on the
ARTG7 (Fig. 1, Table 2).
1.1.1 VenaSealTM
VenaSealTM was initially developed by Dr Rodney Raabe, the original founder of Sapheon
Inc. along with several co-founders Don Crawford, Monte Madsen, Bruce Choi and Nate
Raabe. Sapheon Inc. was later acquired by Covidien in 2014, itself subsequently acquired
by Medtronic (Minnesota, USA). This product obtained CE (Conformité Européene)

9

marking in 2011 and then received registration with the TGA in 2012 as a medical device
(Table 3). The FDA approved the VenaSealTM system in 2015 and approval was granted
in the Russian Federation in 2017 8. The product is currently in clinical use across most
continents.9
The VenaSealTM system is a catheter-assisted endovenous method to deliver n-BCA. The
n-BCA is delivered via a dispensing gun that is attached to the delivery catheter. The
sheath and dilator are high density polyethylene (HDPE) and the delivery catheter is a
polytetrafluroethylene (PTFE) product.
Compared to other products in this category, VenaSealTM has the highest viscosity and
longest polymerisation time and hence is the slowest to act. Polymerisation begins
approximately five seconds after contact with a liquid containing water (such as blood)
and extends to three minutes for nearly complete polymerisation (Table 2). The high
viscosity of the agent works to prevent extension of the adhesive process to adjoining
non-target vessels.
1.1.2 VenaBlockTM
This product was developed by Invamed (Ankara, Turkey) and obtained registration with
the TGA in 2016 as a medical device (Table 4). VenaBlockTM is available for both catheterdirected administration as well as direct percutaneous injections. This product is at least
60 times less viscous than VenaSealTM but 20 times more viscous than water. It has a
very short polymerisation time and is the fastest to act, therefore reducing the possibility
of migration and extension (Table 2).
1.1.3 VeinoffTM

10

This product was developed by Invamed for percutaneous injections and was registered
with the TGA in 2017. VeinoffTM is the least viscous and comparatively most flexible
material after polymerisation with a slightly longer polymerisation time and hence slower
action than VenaBlockTM but still faster than VenaSealTM. (Table 2)
1.1.4 Other products
There are new products entering the international market currently not available in
Australasia, and therefore not specifically reviewed in this document. VariClose TM was
developed by Biolas Health Inc. (Ankara, Turkey) and is currently not registered in
Australasia. Another Turkish product, VenexTM has been developed by Vesta Medical
(Ankara, Turkey) is yet to be available in Australia.

1.2

Cyanoacrylates as Embolic Agents

n-BCA products have been used as embolic agents in interventional radiology (IR),
interventional neuro-radiology (INR) and endovascular surgery in the treatment of AVMs,
portal vein system disease e.g. gastric varices and aneurysms amongst others. Several
products are available internationally but only two, Glubran 2 ® and Histoacryl® are
registered with the TGA. Onyx® is also registered with TGA for some of the above
applications but is not a CA.
1.2.1 Glubran 2®
This product was developed by GEM (Viareggio, Italy) in 1998 and was registered with
the TGA in 2009 for internal use in open and laparoscopic surgery and in digestive tract
endoscopy, IR and INR.10
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Glubran 2® is composed of n-BCA in addition with the metacryloxysulpholane monomer,
which makes its polymer more pliable and stable. The polymerisation reaction is a milder
exothermic reaction at 45°C which results in decreased inflammation and histotoxicity
compared to Histoacryl® or Trufill®.11
1.2.2 Histoacryl®
Histoacryl® was developed in 1968 and is distributed by B-Braun Surgical (Ruby,
Barcelona). It obtained re-registration with the TGA in 2013 for embolization of large
oesophageal or fundal varices and fixation of reinforcement material on soft tissue 12.
Histoacryl® is available in both blue and clear colours. Clear colour should be used for
embolisation of superficial lesions.
1.2.3 Trufill®
This product was developed by Cordis (Miami Lakes, USA) and was approved by FDA in
20005. It is indicated for the embolization of cerebral AVMs when presurgical
devascularization is desired. Trufill® is not registered with the TGA.
1.2.4 Onyx®
Onyx® is not a CA but a non-adhesive liquid embolic agent comprised of ethylene vinyl
alcohol (EVOH) copolymer dissolved in DMSO (dimethyl sulfoxide) and suspended
micronized tantalum powder to provide contrast for visualization under fluoroscopy. It was
developed by ev3 Endovascular, Inc. (Plymouth, USA) and is used to treat AVMs and to
occlude vessels where other mechanical agents such as coils and plugs may not be
suitable or available. Onyx® is registered with the TGA.
1.2.5 Co-administration of Contrast Agents

12

Contrast agents are used when the embolization is performed under fluoroscopic
guidance. Contrast agents are mixed with adhesives at the time of the procedure to
achieve radio-opacity and to alter polymerisation time. Iodised oil (Lipiodol; Villepinte,
France) is a popular contrast agent mixed in various ratios with n-BCA before delivery.
Warming Histoacryl® and lipiodol mixtures to temperatures close to 40°C decreases the
viscosity and makes the injection easier to manage13.

1.3

Cyanoacrylates as Skin Adhesive Agents

n-BCA has been used as a wound adhesive agent for the closure of surgical wounds as
well as trauma-induced lacerations in areas of low skin tension that are simple,
thoroughly-cleansed and have easily approximated skin edges. Histoacryl® and Indermil®
are registered with the TGA in Australia for this purpose.
1.3.1 Histoacryl®
Histoacryl® was registered as a wound adhesive by the FDA in 2007 14 It is indicated for
closure of minimum tension wounds from clean surgical incisions and simple, traumainduced lacerations.
1.3.2 Indermil®
This product was developed by Henkel (Dublin, Ireland) and is registered with the TGA 15
1.3.3 LiquiBand®
This product was developed by Medlogic (Plymouth, UK) and was approved by the
Medicines and Healthcare Products Regulatory Agency (MHRA) of the United Kingdom
(UK) in 2005. It is indicated for the use in laparoscopic surgical repair of inguinal hernia.
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1.3.4 PeriAcryl®
PeriAcryl® was developed by GluStitch Inc. (Delta, Canada) and was approved by FDA in
2007 to assist in securing periodontal dressings.
1.3.5 GluStitch®
This product was also developed by GluStitch Inc. (Delta, Canada) and was approved by
the FDA in 2015 for closure of skin incisions and trauma-induced lacerations.
1.3.6 Dermabond®
This is not an n-BCA, rather, an octyl-CA manufactured by Ethicon (Somerville, USA)
registered on ARTG as a Medical Device Class IIa, 171563, adhesive for soft tissue
approximation. The rate of contact dermatitis has been suggested to be the highest of all
CAs used in medicine reaching up to 2%.16

1.4

Acrylates as Adhesives in Tapes and Dressings

Two groups of compounds are used as adhesives in dressings and bandages including
acrylates and epoxies. CA in general are not used in dressings but other acrylates such
as methacrylates are. The potential for cross-reactivity between CA and other acrylates
is discussed under 1.7.5.
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2.

BASIC SCIENCES

2.1

Basic Physiochemistry

Acrylates are plastic compounds commonly found in artificial nail products, paints,
varnishes and adhesives. They have numerous applications in medicine, dentistry and in
the printing industry.
2.1.1 Molecular structure
Acrylic acid contains the vinyl group CH =CH− connected to a carboxylic acid −COOH
2

terminus forming the molecule CH =CH−COOH. Acrylates are salts, esters or base
2

conjugates of acrylic acid. CA is an ester −COO− derivative of acrylic acid. The ester
group is called carbonyl. The carbonyl group −COO− connects to an alkyl group −R that
can be of various lengths (−COOR). One carbon atom would create a methyl-CA
−COO−CH

derivative. Increasing the length of the carbonyl produces ethyl

2

(−COO−CH −CH ) and butyl −COO−(CH ) derivatives. The molecule also contains a
2

2

2 4

cyano-group (nitrile; −C≡N) (Fig. 2A). Hence, the general formula of CA is
CH =C(CN)−COOR.
2

The non-medical adhesive, ‘Super Glue’ is ethyl 2-CA. All commercial systems currently
used in Australasia for venous closure are n-BCA containing the butyl group (−C H ) (Fig.
4

9

2B). n-butyl stands for normal butyl or −CH −CH −CH −CH and implies the butyl group is
2

2

2

3

organised in a linear hydrocarbon chain of four carbon atoms.
2.1.2 Antigenicity and the Molecular structure
The antigenic component of acrylates is thought to be the carboxyl ethyl
(−COOH−CH −CH ) functional group. The molecule is less likely to be allergenic if the
2

2

15

hydrocarbon chain is longer than an ethyl group. The extra length results in the masking
of the antigenic group. Hence, an acrylate containing a carboxyl butyl group such as nBCA has less potential for allergenicity than one containing an ethyl group.
2.1.3 Polymerisation of Cyanoacrylates
CA are produced as liquid monomers that when exposed to ionic surfaces readily join to
polymerize and form long chain polymers. Exposure of CA monomers to an anion, such
as the hydroxyl (−OH) group in water, initiates the polymerisation process with bonding
of the ethylene units (Fig. 2C). The polymers form strong resins and effectively adhere
closely spaced surfaces14. CA polymers bond almost instantly to a variety of surfaces
including plastic, metal, glass and biological materials.
The polymerisation process is an exothermic reaction releasing heat during the process.
Temperatures can reach 40-45ºC in the peri-venous space causing mild discomfort, but
the heat is not sufficient to damage any adjacent structures. A longer hydrocarbon length
results in a slower rate of polymerisation and less exothermic reaction.17
2.1.4 Production
There are several known methods of synthesizing CA monomers. The following sequence
is usually followed in the industrial production of CA:
1. Reaction of formaldehyde with a cyanoacetate ester to produce the 2-cyanoacrylate
ester, which spontaneously polymerizes.
2. Thermal depolymerisation into a liquid monomer. This is typically done under acidic
conditions and in the presence of an inhibitor such as sulfur dioxide, phosphorous
pentoxide, or nitric oxide to generate the monomer.
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3. Modification of the monomer by altering the carbonyl (−COOR) group to obtain
compounds with different chain lengths.
4. Addition of additives, stabilizers and thickeners to modify viscosity, polymerisation time
and performance properties such as the bond strength. The additives play a major role in
determining the final physiochemical properties of these products.
2.1.5 Proprietary Information
Commercially available medical-grade CA are defined by their composition, viscosity,
polymerisation, pliability, tensile strength and adhesion strength. Much of this information
is classified as confidential and is not available to the public or the practicing physicians.
This information was requested by the panel to both of the manufacturers of endovenous
glues registered with the TGA (Appendix 1) but the data was considered proprietary
information and withheld.

2.2

Mechanism of Action

n-BCA are delivered intravascularly to induce a mechanical occlusion of the target vessel
or lesion, resulting in obstruction to flow. Following entry into the target vessel, the
delivered product forms a cast which may adjust to the shape of the vessel lumen. With
direct percutaneous injections into smaller calibre vessels using faster polymerising
agents, adjusting to the shape of vessel may not happen unless significant compression
is applied at time of injection. Under low shear conditions, such as that found in veins, the
formation of the cast is sufficient to induce obstruction, resulting in vessel closure and
interruption of flow. It has been argued that in high shear conditions such as in an AVM
or arterial aneurysm, the introduction of the n-BCA is insufficient to cause permanent
occlusion unless additional products such as metal coils or detergent sclerosants are co-
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administered18. The n-BCA is then thought to induce necrosis of the intimal layer,
resulting in an inflammatory process that ultimately leads to vascular fibrosis. Vascular
endothelial damage is caused by chemical and/or heat-based reactions resulting in acute
necrotizing vasculitis.19 In low shear conditions as in veins or venous malformations,
intravascular thrombus formation may also contribute to endothelial damage.

2.3

Tissue Response to Cyanoacrylate

The histopathological response that follows the introduction of n-BCA in blood vessels
has been investigated in multiple studies, mostly involving AV malformations and
oesophageal varices. Currently, there are only two studies describing the histology of
a truncal vein following its treatment with n-BCA. The first is a Russian study where
the vein was dissected after 10 minutes of exposure to Venaseal TM.20 The second is an
Australian study where serial biopsies were taken at 1 week, 6 weeks and one year after
VenablockTM treatment of peripheral veins 21.
The Russian study reported mast cell degranulation in the peri-vascular space within 10
minutes of exposure to glue

20.

In AVM studies, acute inflammation consisting mainly of

polymorphonuclear (PMN) cells was observed with foci of intramural haemorrhage within
24-48 hours of n-BCA injection

22, 23.

In the Australian study using VenablockTM, the first

week biopsy revealed the injected n-BCA in the vein lumen to be coated with erythrocytes.
No histiocytes or granulomas were present at this stage.21 The AVM studies showed that
by weeks 2-3, there was a granulocytic infiltration of vessel walls and the peri-vascular
tissue. The vessel wall showed patchy loss of intima, medial necrosis, as well as early
foreign body giant cell formation and round-cell infiltration 22-24. In the Australian study, by
6 weeks, the n-BCA was still present in the vein lumen, adherent to fibrinous material and
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erythrocytes. No granulomatous reaction was seen at this stage but small luminal foci of
isolated foreign body histiocytes were present 21. The AVM studies showed that by week
8, mural angionecrosis was completely replaced by fibrosis with segmental wall
thickening, achieving venous closure. Foreign body giant cells were present.25, 26 The
one-year biopsy in the Australian study revealed a lack of endothelial lining in the treated
vessels, but there was lymphoid hyperplasia and fibrosis of the surrounding tissue.
Significantly, there was extrusion of n-BCA to the peri-vascular space and extra-vascular
cavitated foreign body granulomas with foreign body-type giant cells. These features
were not present in the one week and six-week biopsies from the same patient implying
that the glue extrusion is a long term finding. In the Australian study, all granulomas were
found to be extra-vascular and not observed in the vessel walls or within the lumen of the
treated vessels and hence there was no evidence of a granulomatous phlebitis

21.

The

foreign body granulomas were observed for as long as 52-60 months.

2.4

Hypersensitivity and Immune Response to Cyanoacrylate

2.4.1 Type I Hypersensitivity
Type I Hypersensitivity, also known as immediate-type hypersensitivity is an IgEmediated immune response typically occurring within minutes after the antigen interacts
with the IgE molecule attached to the mast cell surface. There is an immediate release of
vasoactive amines such as histamine, and other mediators such as heparin and tryptase
followed by a later recruitment of inflammatory cells. Prototypical disorders include
anaphylaxis, urticaria and bronchial asthma. Type I reaction can be clinically detected by
skin prick testing and measurement of serum IgE and serum and urinary tryptase.

27
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Histopathologically, Shaidakov et al. demonstrated active mast cell degranulation in the
removed extra-fascial segment of the GSV within 10 minutes of VenaSeal TM n-BCA
injection.20 Additionally, Korkmaz et al.

28.

found eosinophilia two hours after the CAC

procedure.
To date, there have been no clinical reports of anaphylaxis to n-BCA, and only a few
documented allergic reactions exist in the English literature of transient total body urticaria
29, 30

and asthma31.

2.4.2 Type IV Hypersensitivity
Type IV hypersensitivity, also known as delayed-type hypersensitivity is a T-cell mediated
immune response occurring within 24-48 hours. Allergic contact dermatitis (ACD) is a
prime example of a type IV hypersensitivity reaction. 27
Acrylates were named “Contact Allergen of the Year” in 2012 by the American Contact
Dermatitis Society due to their ubiquity in the modern-day environment

32.

ACD to CA-

based medical adhesives has been frequently described in the literature, with Dermabond
(2-octyl CA) being commonly implicated in numerous cases of tissue adhesive contact
hypersensitivity

33.

In addition to CA, extensive reports of occupational and non-

occupational ACD to acrylates including methacrylates, ethyl acrylates, ethylene glycol
dimethacrylate, have been published in dentists, dental technicians, printers, fibreglass
workers, beauticians and women who are in contact with manicured/sculptured artificial
nails.34 ACD caused by acrylates is common in dental personnel and may present with
respiratory or conjunctival symptoms.35
It is strongly recommended that professionals using acrylates avoid touching the product
to prevent sensitisation.
20

2.4.3 Irritant Contact Dermatitis (ICD)
Other than ACD, acrylates can cause irritant contact dermatitis (ICD). The skin reaction
to most medical adhesive tapes, dressings and bandages is primarily an ICD36. The
adhesive used in medical tapes is in general either an acrylate or an epoxy. ICD is more
frequent with the use of reactive-type acrylates containing methacrylate monomers and
oligomers and polymerisation initiators and additives. Acrylate monomers are strong
irritants and are responsible for most of the documented cutaneous reactions.

34

In

general, monomers with polarity and lower molecular weights tend to present a greater
potential for skin irritation. By contrast, completely cured acrylic polymers are relatively
inert.
ICD from medical personnel manipulating n-BCA is rare, however it is quite likely that
some of the reported cases of ‘phlebitis’ following the use of n-BCA in peripheral veins
may be due to ICD. In such cases, the presenting sign of ‘phlebitis’ has been erythema
in the absence of venous inflammation. Further studies are required to investigate this
finding.
2.4.4 Prick and Patch Testing
Although rare, acrylates may trigger an immediate hypersensitivity reaction but acrylates
are not part of the standard skin prick test panels. If performed using the n-BCA product
itself, a negative prick test would not exclude a delayed type hypersensitivity, which is the
more common reaction to acrylates.
Commercially available patch test series for acrylates include multiple compounds
including methyl methacrylates (MMA), ethyl methacrylate (EMA) and ethyl CA but
currently do not include n-BCA.37. When patch tested, acrylate-allergic patients often
21

display multiple positive tests. These reactions may represent cross-reactivity, or a
reaction to a concomitant product or impurity that is not disclosed in the material safety
data sheet. 38.
Acrylate monomers should not be deliberately applied to the skin for patch testing as this
may sensitise the individual, causing a new allergy. All those handling acrylate monomers
should avoid direct skin contact with them.
2.4.5 Cross-reactivity of Acrylates and Cyanoacrylates
Acrylate cross-reactivity is thought to be due to the carboxyl ethyl −COOH−CH −CH
2

2

functional group (Fig. 2B). The carboxyl ethyl group is the requisite for antigenicity as it
reacts with receptors on antigen presenting cells (APC)

39.

Further, this functional group

needs to be exposed on the end of the molecule for it to be detectable by APCs.
Molecules with a carboxyl group where the alkyl component is longer than ethyl (two
carbon atoms) will not cross-react. For example, if the side group is carboxyl butyl (COOH−CH -CH -CH -CH ), despite it containing the antigenic carboxyl ethyl group
2

2

2

2

(−COOH−CH −CH ) within it, the additional ethyl group at the end makes the functional
2

2

group too large and hydrophobic, concealing it from the APCs. In other words, ethyl-CA
is much more likely to be antigenic and cross-react with other acrylates compared with
butyl-CA. Nonetheless, n-BCA may cross-react with other acrylates as it contains the
antigenic carboxyl ethyl group. The cross-reactivity potential should not be
underestimated in the clinical setting as the n-BCA is intravenously injected as a
“permanent implant” with a potential life-time of exposure and risk of sensitisation is
directly related to duration of exposure. Manufacturers of medical-grade n-BCA, in
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particular VenaSealTM and VenaBlockTM recommend against the use of this product if the
patient has a known allergy to an acrylate.

2.5

Toxicology and Antimicrobial Properties

2.5.1 Toxicology
All occlusive agents licensed for peripheral venous applications are registered with
regulatory bodies as devices and not as drugs and hence have undergone a different
pathway of registration compared with that required for new drug licensing. Changes to
the preparations made by the companies to make them commercially acceptable remain
confidential and hence the additives and excipients that define the viscosity and the
physiochemical properties of each product are not disclosed. Given the reports of n-BCA
migration and pulmonary embolism (PE) following their use in gastric varices, the
modifications of CA products have mostly been aimed at viscosity and polymerisation
time and have mostly focused on modifications in the composition of the additives

40.

Toxicology of all registered endovenous glues was established on unpublished in-house
studies, required as a part of the submission to notified bodies and regulatory agencies.
The US National Toxicology program has extensively studied ethyl-cyanoacrylate and
methyl 2-cyanoacrylate, particularly for potential mutagenic and carcinogenic effects
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and these compounds are not considered to be a problem for use in humans.
2.5.2 Antimicrobial Properties
The bacteriostatic and bactericidal properties of n-BCA have been documented
extensively in the ophthalmic literature in the context of sealing corneal incisions, both in
vivo and in vitro.42-46 The n-BCA inhibited the growth of gram-positive organisms including
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staphylococcus aureus, streptococcus pyogenes and streptococcus pneumoniae 43 but
had less effect on gram-negative organisms including pseudomonas aeruginosa and
escherichia coli. 42
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3.

CLINICAL STUDIES

3.1

Observational Studies

Several studies have shown that CAC is clinically safe and effective with cumulative
occlusion rates comparable to those for ETA. The initial study by Almeida et al.47,

48

reported a 36-month cumulative occlusion rate of 94.7% in 29 of 38 patients with GSV
reflux treated by CAC. This study showed no more than mild to moderate adverse effects.
No peri-venous tumescent anaesthesia (TA) or graduated compression stockings (GCS)
were used. A multicentre European trial presented by Proebstle et al.49 reported a
cumulative 12-month occlusion rate of 92.9% in 70 GSVs. No GCS or TA was used and
a phlebitic reaction occurred in 11.4% with a median duration of 6.5 days. Two
independent Turkish studies showed similar results with different techniques. One study
with 62 patients with GSV reflux showed a six-month total occlusion in 90.3% and subtotal
occlusion (flow in a 5-10 cm segment of treated vein) in 6.5%.50 Another study of 180
patients with GSV reflux treated by VariCloseTM showed a 30 months cumulative
occlusion rate of 94.1%.51
An American study reported early outcome for 70 veins treated including GSV, SSV and
anterior accessory tributary of GSV (AAGSV) measuring up to 20mm diameter. 29 GCS
were not used and phlebitis in the treatment area or tributaries occurred in 20% but
completely resolved in all but one patient by one month. All veins were occluded at one
month and adjunctive procedures for tributaries decreased from a predicted 96% to an
actual 74%. Mean time to return to work and normal activities was less than three days.
A single-centre study of 57 legs treated for GSV reflux in Hong Kong showed a 78.5%
closure rate at one year.52 Mean vein diameter ≥8mm was a significant predictor for
25

recanalization. A study from the Netherlands showed that it is feasible to use CAC to treat
incompetent perforators.53

3.2

Randomised Trials

A collaborative trial involving 10 centres in the USA treated 222 patients with GSV reflux
in veins up to 12mm diameter randomised to CAC or radiofrequency ablation (RFA). 54
There were identical occlusion rates at 12 months (CAC 97.2%: RF 97.0%). There was
comparable improvement of symptoms and quality-of-life in both groups and adverse
effects for CAC were mild to moderate.
A Turkish trial studied 310 patients with GSV reflux treated with CAC or EVLA. The oneyear closure rate for CAC was 95.8%. Operative time was shorter (15±2.5 vs 33.2±5.7
minutes respectively) and periprocedural pain was less (3.1±1.6 vs 6.5±2.3 respectively)
for CAC.55 Another larger Turkish trial with 456 patients, with a two year follow up
compared CAC with RFA and EVLA with treatment of superficial venous incompetence
reported No differences were observed in occlusion rates between the three modalities,
but CAC appeared superior with respect to peri-procedural pain, return to work and
decreased VCSS.56
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4.

COMPLICATIONS

Medical uses of CA have been associated with a wide range of complications when used
in different settings and for various applications. Some of the reported complications are
due to mixing the agent with contrast agents such as lipiodol and not due to the CA itself.
Some of the complications may also be due to the additives but there is insufficient data
to discern the effect of the additive as against the compound itself. Here we focus on
complications of CAC for treatment of peripheral veins and briefly review complications
associated with their use as embolic and adhesive agents.

4.1

Complications of CAC

The most common complication of CAC is phlebitis, reported at a rate of 11.4% in the
study by Almeida et al.

57

and 20% in a study by Morrison et al.

54.

CAC is heavily

marketed with a claim that it does not require the concomitant use of GCS or TA 58. The
nature of phlebitis following CAC may be related to a hypersensitivity reaction described
below and not necessarily a superficial thrombophlebitis (STP) due to thrombus
formation. In comparison, phlebitis following EVLA is reported at 7.7% 55, 59-7.9%60 and
following RFA at 14%54. The treatment protocols of both EVLA and RFA require the use
of GCS and TA. Whether the relatively high incidence of phlebitis post-CAC is due to lack
of compression or a hypersensitivity-type reaction is yet to be determined. Immediate and
delayed hypersensitivity reaction with granuloma formation in particular have been the
most significant concern of clinicians. Other than hypersensitivity and phlebitis, CAC is
associated with other complications, summarized in Table 5.
4.1.1 Hypersensitivity reaction
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Anaphylactic reactions to CA and death from anaphylaxis have not been reported. Allergic
reactions to CA are rare and although true incidence is not known, there has only been
few documented cases in the English literature of transient total body urticaria
contact dermatitis

33, 61, 62

29, 30,

and asthma31. The authors of the current consensus have

reported incidences of pruritus without a rash following VenaSealTM and VenablockTM
treatment. Sensitisation to other acrylates has been extensively reported in beauticians
and dental workers and even recreational users with frequent exposure to false acrylic
nail or eyelash glues, gel nail polishes or dental fillings

35, 63-65.

Contact dermatitis is the most common manifestation (80-93%) 64, followed by dyshidrotic
eczema (pompholyx) (9.1%)64 and very rarely asthma and rhinoconjunctivitis35, 66. A UK
and Irish audit of 4931 patients found a patch test positive rate of 2.4% to at least one
type of (meth)acrylate. In the audit, 60% of people developed their allergy through
recreational exposure, 33% through occupational and 7% through medical adhesives. 1 A
history of hypersensitivity reaction to acrylic nails and the glue used for eyelash
extensions is an absolute contraindication to CAC. However, there is a paucity of
information on possible cross-reactivity between medical adhesives used in dressings
and cyanoacrylate products.
4.1.2 Hypersensitivity-type phlebitis (HTP)
Phlebitis is consistently the most common adverse event following CAC, reported in 120% of cases29, 47, 48, 50, 52, 54, 55, 57, 59, 60, 67-69 (Table 5). The literature is not very specific on
whether the reported complications are true phlebitis (inflammation of the vein) or an
immune skin reaction resembling phlebitis. This is highlighted by the fact that “phlebitis”
may be noticed at the site of the treated vein or at distant untreated sites. When the
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phlebitis has involved treated veins, it has been responsive to NSAIDs whereas some of
the phlebitis-like-reactions clinically presenting with erythema, oedema, pruritus and
tenderness have been unresponsive to NSAIDS. In a study by Morrison et al. the phlebitis
post VenaSealTM CAC was classified as phlebitis occurring in the treated site as against
those occurring over untreated sites. One third of all phlebitis reactions occurred in
untreated sites. In a study by Gibson et al., phlebitis was classified as those occurring at
the treated vein, those occurring at adjoining tributaries and a non-specific erythematous
skin reaction occurring at other sites. Similarly, one third of the reported phlebitis reactions
had the non-specific erythematous reaction.

29, 57, 68.

In a report by Zierau et al.,

unspecified, inflammatory reddening of the skin was observed approximately five to eight
days post-surgery in 11.7% of cases70. Park et al.
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recently identified such reaction as

a separate entity from true phlebitis. He postulated that it is a type IV delayed
hypersensitivity reaction due to a foreign material, rather than localised inflammation and
named it phlebitis-like abnormal reaction (PLAR). The reaction he described was bilateral,
pruritic and was alleviated by antihistamines and steroids in over 85% of patients. It
occurred more commonly following CAC treatment of extra-fascial veins than sub-fascial
veins. The fact that this reaction responded to antihistamines suggests a more immediatetype hypersensitivity response rather than a delayed type. Consistent with this finding,
Shaidakov et al.20 found active degranulation of mast cells in the removed extra-fascial
segment of the n-BCA-treated vein. Further, Korkmaz et al.

28.

found eosinophilia two

hours after the CAC procedure.
In summary, it is likely that hypersensitivity-type phlebitis (HTP) is a separate entity to
conventional phlebitis, as it is driven by cell-mediated reaction to foreign body material.
Given the timing of pruritus and its responsiveness to anti-histamines, it is possible that
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the hypersensitivity reaction is a combined type I and type IV response which would
explain the constellation of erythema, oedema, urticaria, pruritus and histological finding
of mast cell degranulation and systemic eosinophilia. This combined pattern of immune
reaction is not uncommon and is seen in atopic dermatitis where the patient can exhibit
both an immediate type hypersensitivity manifested by an urticarial reaction driven by
mast-cell degranulation combined with a dermatitis which is a T-cell driven
hypersensitivity. Therefore, the treatment of such hypersensitivity type reaction should
include the combined use of NSAIDs and oral antihistamines, as well as systemic
immunosuppressant such as oral or IV steroids in severe cases. Procedures must be
performed in controlled environments where resuscitation equipment is readily available,
and the staff are trained and well equipped in dealing with anaphylaxis and
hypersensitivity reactions.
4.1.3 Granulomatous phlebitis
Histological studies have consistently demonstrated a granulomatous phlebitic reaction
developing within two months and evident at 12 months after injection of n-BCA. This
reaction commonly remains asymptomatic but may progress to suppuration, necrosis and
ulceration. Extrusion of the glue from the vein lumen is another important consideration.
A case report by Zernovicky described a 54-year old female treated with VenaSealTM who
developed spontaneous skin perforations with spontaneous evacuation of fragments of
n-BCA from the treated sites on both legs 4 months post-operation

71.

Ultrasound

demonstrated movement of the glue in the terminal part of both GSVs. The progression
continued despite the use of steroids and excision of the initial granuloma and the patient
eventually required bilateral saphenectomy. After dissection of the vein, glue was
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observed to be mobile within the treated vein. 10 days after saphenectomy the pain and
erythema were reduced, but there was long-term residual lymphoedema.
4.1.4 Superficial Thrombophlebitis (STP)
Despite ‘phlebitis’ being the most commonly reported complication of CAC, a range of
skin complications such as ICD as well as true phlebitis appear to have been grouped
together and labelled as “phlebitis” in the published literature. These include HTP,
granulomatous-type phlebitis (GTP) as well as STP. Three of the eleven studies identified
STP as a complication distinct from the non-specific ‘phlebitis’, occurring at a rate of 34%50, 54, 57, 72. Future studies need to clearly differentiate between ICD, ACD, HTP, STP
and GTP.
4.1.5 Deep vein occlusion, thrombosis and embolism
Earlier studies report high rates49, 57 (21%) of n-BCA extension from the saphenofemoral
junction (SFJ) to the common femoral vein (CFV) observed at the 48-hour follow-up on
duplex ultrasound that resolved at 3-month follow-up with anticoagulation.57 This was
likely due to the catheter being positioned 3cm from the SFJ, thereby not providing
adequate room for glue propagation along the GSV. With recent technique modifications
of increasing the distance to 5cm, thread-like thrombus/CAC extension is less likely.50
However, extension of n-BCA from the target saphenous vein into the adjoining deep
veins, ie the CFV or the popliteal vein remains a concern. This is probably more likely
with less viscous products although randomised studies comparing less viscous with
more viscous products are not available. Particular caution with perforator treatment is
required due to the potential risk of deep venous extension but slow careful injection under
real time guidance may reduce the risk.
31

PE following CAC has not been reported.

72

but PE following n-BCA embolization of

gastric varices has been reported40.
4.1.6 Injection site complications
Injection site infections are rare (~1%). Other reported injection site complications include
localised bruising, pruritus, inflammation, vesicles, ischemic ulcer, skin irritation, and
swelling48. Extrusion of a small plug of glue with both VenaSealTM and VenaBlockTM have
been reported by two doctors on the consensus leading to delayed healing of the access
point.
4.1.7 Hyperpigmentation
Hyperpigmentation has a reported incidence of 1.3 55-11.8%.68, resulting from treatment
of a vein coursing close to the skin surface such as the epifascial GSV. 57 Some
hyperpigmentation has been transient55, while others were still visible one year posttreatment57.
4.1.8 Paraesthesia
Two studies have reported paraesthesia with rates of 0-3%54,

69.

In both studies, the

paraesthesia was mild and transient.
4.1.9 Oedema and lymphedema
Members of the panel have reported incidences of oedema following VenaSeal TM
treatment in the absence of deep vein occlusion or HTP. This may be due to an
exaggerated inflammatory response to CA. Lymphedema was reported following the case
of suppurative granulomas by Zernovicky 71.
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4.1.10 Palpable nodules
Members of the panel have reported palpable nodules along the length of the treated vein
following VenaSealTM, VenaBlockTM and VeinoffTM treatments with some nodules
requiring excision or phlebectomy. This could be due to the proximity of the vein to the
skin surface. Palpable nodules have also been reported due to extension of the glue into
superficial tributaries when injecting perforators and truncal Veins.
4.1.11 Skin discolouration
There are no reports of skin “tattooing” from the use of n-BCA in the setting of endovenous
injection. However, there have been reports of tattooing of the skin from when Histoacryl
Blue was used as an embolic agent close to the skin 73. A theoretical advantage of
VenaSealTM over VenaBlockTM or VeinOffTM is its clear colour, whereas the other two
products are blue (Fig. 1). It is worth noting that Histoacryl clear is available.

4.2 Complications in Embolic Use
Reported complications of CAC in its use as an embolic agent have included tissue
ischemia, end-organ infarction19, PE

40,

cerebral infarction74, haemorrhage7, and rupture

of AVMs due to increased intranidal pressure. Systemic reactions have included nausea,
vomiting19 and fever, while other local complications include regional pain, catheter
retention75, reflux, blockage or adhesion to vascular walls.19 When used to treat
superficial vascular malformations, n-BCA have been associated with suppuration,
palpable cast formation and tattooing of the skin with blue histoacryl®. It should be noted
that when used with fluoroscopic guidance, n-BCA are mixed with lipiodol and some of
the above reactions may be due to the contrast agent.
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4.3 Complications in Adhesive Use
Reported complication of CAC in its use as an adhesive for wound closure has been
limited to contact dermatitis and allergic reactions.14, 76
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5. TREATMENT PROTOCOLS
5.1

Preoperative Assessment

5.1.1 Initial Consultation
•

A complete medical history and physical examination (with specific reference to
Section 5.2: procedural indications and contraindications) should be performed
before treatment is offered.

•

CEAP classification should be recorded.

•

Photographs of lower limbs and other relevant photographs should be obtained.

5.1.2 Preoperative Duplex Mapping
•

Comprehensive duplex ultrasound (DUS) venous incompetence studies should be
undertaken to map out the pathway of venous incompetence, exclude venous
thrombosis and confirm suitability for intervention.

•

DUS should be performed within one year of proposed treatment and repeated if
the lapsed period is longer than 12 months.

•

Copies of the diagnostic findings and proposed treatment plan should be sent to
the referring practitioner.

5.1.3 Patch testing
•

Patch testing to acrylates can be organized at the discretion of the clinician
following open disclosure of the incidence of hypersensitivity reactions with the
individual patient.

•

A negative patch test does not eliminate the possibility of granuloma formation or
glue extrusion or perforation.
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•

Referral to immunologists or contact dermatologists should be considered in high
risk patients.

5.1.4 Post-Investigations Consultation
•

This consultation should include a discussion of the clinical, ultrasound findings
and patch-test findings, if performed.

•

Open and unbiased discussion of alternative treatment options including
conservative measures to manage chronic venous insufficiency (CVI). At this
stage, it would be inappropriate to strongly recommend CAC over ETA although
other treatment options such as open surgery are considered to be less
favourable.77-82

•

Discussion of the risks and complications of each treatment option and possible
remedial actions in the event of adverse outcomes.

•

Discussion and documentation of patient’s expectations with advice as to whether
they are realistic and achievable.

•

Discussion of life-style modifications during the treatment period, travel, pregnancy
and other factors that might influence or interrupt the treatment.

5.1.5 Financial Consent and Cool Off Period
•

A written estimate of cost for the anticipated course of treatments should be
provided.

•

The patient must be given adequate time to understand the information provided,
ask questions and seek a second opinion if required.

36

•

Treatments should ideally not be performed on the same day as the consultation,
unless there are compelling reasons to do so.

•

If performed for cosmetic reasons, the Medical Board of Australia stipulates there
should be a cooling off period of at least seven days between an adult patient
giving informed consent and a major procedure. For minors under the age of 18,
there must be a cooling off period of at least three months before a major
procedure, and evaluation by a general practitioner, psychologist or psychiatrist is
mandatory.

5.1.6 Informed Consent
•

Informed consent should be obtained prior to every procedure.

•

The discussion should include an explanation of the treatment technique provided
in lay language, discussion of adverse events, alternative treatment options and
the option of conservative measures such as GCS or no treatment if appropriate.
Financial consent should be obtained prior to every procedure.

•

It should be explained that long-term data regarding the fate of the treated veins
is unavailable, and the possibility of severe and cosmetically disfiguring
complications must be discussed especially for asymptomatic C1-C2 patients who
may be presenting for cosmetic reasons.

5.2 Indications and Contraindications
5.2.1 Indications
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5.2.1.1

Saphenous Reflux- All TGA recognised glue products in Australia are

registered for the treatment of saphenous reflux.
5.2.1.2

Venous Tributaries- VenaBlockTM and VeinoffTM can be directly injected and

hence are registered with TGA for the treatment of tributary veins and perforators. Off
label use of Venaseal(™) via direct injection has been reported.
5.2.2 Contraindications
The list of contraindications provided here needs to be revised on a regular basis to reflect
clinical and scientific evidence for precautions as further knowledge is obtained. Individual
practitioners should exercise care using CAC, bearing in mind that n-BCA are implantable
foreign bodies that trigger an immune or hypersensitivity reaction. This reaction may
remain clinically silent or may become clinically detectable. Caution should be exercised
when using n-BCA in higher risk patients and n-BCA should only be used when there are
no reasonable alternatives to treatment and a full disclosure of risks is discussed.
5.2.2.1

Hypersensitivity

History of immediate (urticarial) or delayed hypersensitivity reactions to acrylates and
commercial or medical grade CA preparations. This includes, but is not limited to, a
previous reaction to household ‘Super Glue’ preparations, glue used for eyelash
extensions or glue used in acrylic, signature nail systems (SNS) and shellac nail
preparations.
5.2.2.2

Previous significant adverse reactions to CAC

This includes adverse events such as extensive ‘phlebitis’, necrosis, suppuration,
oedema and other such reactions.
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5.2.2.3

Acute venous thromboembolism (VTE)

This includes deep vein thrombosis (DVT), pulmonary embolism (PE) and superficial
thrombophlebitis (STP)
5.2.2.4

Active or uncontrolled systemic disease

This includes systemic inflammatory disorders, un-controlled systemic autoimmune,
granulomatous, hypersensitivity or mast cell disorder including vasculitis, mastocytosis,
sarcoidosis, systemic lupus erythematosus (SLE), atopy and granulomatous disease or
infections. In particular we advise against the use of CAC in patients with a history of
sarcoidosis where the antigen remains unknown or various antigens are implicated. We
also recommend granulomatous vasculitic disorders such as Wegener’s granulomatosis
or Churg-Strauss disease should be considered an absolute contraindication.
5.2.2.5

Acute or un-controlled localised or systemic infections.

This includes cellulitis in the affected leg, widespread folliculitis and organ-specific
infections.
5.2.3 Warnings and Precautions
5.2.3.1

Pregnancy

Treatment in the first trimester is a contraindication. Treatment in the third trimester
should only be delivered for medical indications where there is no other treatment option
available.
5.2.3.2

Breastfeeding within 48 hours of the procedure

There is no data on the excretion of the n-BCA or the product additives in breast milk.
Venous interventions in the first three months postpartum should be avoided due to the
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increased risk of VTE. Afterwards venous interventions should only be performed for
significant medical reasons while the patient is breast-feeding. In such situations, a pump
and store strategy would provide the mother’s milk to be used via bottle feeding. For 48
hours following intervention, breast milk should be pumped and disposed of.
5.2.3.3

Low body fat percentage

Patients with reduced subcutaneous fat or thin legs can frequently feel the firm cord of
the treated vein along the thigh and ask whether this will disappear. Accordingly, patients
with low body fat percentage (<10%) or thin legs may constitute a relative contraindication
to CAC.
5.2.3.4

Systemic autoimmune disorders

Care should be taken in treating such patients with n-BCA and consideration to pre and
post treatment steroid administration should be given. Until further data on the safety of
n-BCA in patients with autoimmune disease is available, ETA should be offered as the
first option and CAC should be offered when there are no other safe treatment options
available.
5.2.3.5 Thrombophilia and hypercoagulable state
In patients predisposed to VTE, prophylactic anticoagulation for seven days
postoperatively should be offered.

This includes documented known significant

thrombophilias, immobility including long-haul travel of more than five hours continuous
travel, not including travel on ships or trains, within a two-week period. Treatment in
patients with active malignancy or those on tamoxifen should be performed with care and
prophylactic treatment with low molecular weight heparin (LMWH) should be provided for
seven postoperative days.
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5.3

Techniques: General Considerations

The following summary of techniques are those recommended by the manufacturers. It
does not provide sufficient information to perform the procedures, and this must be gained
by hands-on supervised training. Variation of techniques can be considered based on the
practitioner’s experience.
5.3.1 Technique Overview
CA are liquid polymers that polymerise on exposure to free radical and anions. Care
should be taken not to draw up the product in a catheter or syringe flushed with saline,
water or containing blood. When used for vascular embolization, n-BCA is delivered via
selective catheterisation where the catheter is flushed with 5% dextrose prior to delivery
of the combination of n-BCA and lipiodol. However, when used for peripheral venous
interventions, n-BCA is delivered via non-stick special purpose made catheters to avoid
catheter retention and adhesion to vessel wall. The technique is promoted as a ‘nonthermal non-tumescent (NTNT) procedure not requiring post-operative compression.
Practitioners should exercise caution, common sense and good medical practice when
customising the treatment to individual patients’ needs, anatomy and pathology.
5.3.2 Dose
There is no scientific data regarding the maximum dose of n-BCA per treatment session.
The consensus group has stipulated an arbitrary upper limit of 10 mL of adhesive per
CAC treatment session based on practical considerations and vein length. The safe lifetime upper limit of n-BCA is not known.
5.3.3 Peri-venous Tumescent Anaesthesia
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TA has been routinely used in conjunction with ETA to provide anaesthesia, target vein
compression and heat dissipation reduction. Polymerisation of n-BCA is exothermic at
temperatures of 40-45 C in the peri-venous space. Given that CAC does not generate
0

significantly high temperatures and is not a painful procedure, TA has not been routinely
used in conjunction with CAC. Peri-venous TA should be considered when treating large
diameter veins, particularly for limited use at sites of vein dilatation and at the saphenous
junctions, to ensure vein closure, reduce the risk of embolization and to reduce the volume
of n-BCA required.
5.3.4 Graduated Compression Stockings
Reported incidence of phlebitis post CAC is up to 20% whereas by comparison the
incidence of phlebitis in EVLA is up to 7.9%60 and for RFA is up to 14%54. While phlebitis
post CAC may be due to HTP, it is unknown whether the lack of compression contributes
to this high incidence of phlebitis. GCS are not recommended by the manufacturers but
should be prescribed if there is an increased risk of phlebitis, inflammation, pigmentation
or DVT, if there are other endovenous procedures performed concurrently or if the patient
prefers to wear compression for comfort reasons.
5.3.5 Documentation
Make a written record of the following:
•

The date and time of the procedure

•

The treated leg(s)

•

The treated vein(s)

•

The length and diameter of veins treated

•

The type and the brand name of the n-BCA used
42

•

Retain the product label and stick it on the operation report to document the batch
number which will be required in the case of an adverse reaction.

•

Dosage of n-BCA used

•

Details of any other concurrent or adjunctive procedures performed

•

Whether or not compression was applied

•

Any immediate adverse reactions

•

Post-treatment management.

5.4

Catheter-Directed Treatment of Saphenous Reflux

Catheter directed n-BCA (VenaSealTM and VenaBlockTM) can be used to treat saphenous
reflux as an alternative to ETA or surgical stripping. Catheter-directed CAC should be
performed in operating theatres, hybrid theatres or appropriately equipped and staffed
outpatient procedure rooms with access to appropriate resuscitation equipment. We
consider that it is a requirement to use full sterile surgical technique of gowning and gloves
for all operating members including assisting sonographers and scrub nurses. Ultrasound
equipment used must include a high-frequency linear array probe with colour flow and
Doppler capabilities, and the probe must be in a sterile sheath.
5.4.1 VenaSealTM Procedure
The procedure involves an introducer sheath, a dispensing catheter, and a 3mL syringe
to be attached to a dispenser gun. The total amount of adhesive to be delivered in one
treatment session needs to be calculated as a function of the vein length and diameter.
A total of 5mL of glue is provided in one package, 1.4mL of which is wasted in the dead
space of the catheter. The remaining 3.6mL can be used to treat up to 90cm of vein length
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if the vein diameter is less than 6mm. When treating two legs, 10mL of glue will be
required, 8.6mL of which can be used considering 1.4mL is wasted in the catheter deadspace. This allows for treating larger lengths of target veins and vein of larger diameter
(discussed below where 0.1mL of n-BCA is injected at 2cm intervals)
•

Select the access point based on the clinical indications and the treatment plan.

•

Inject local anaesthetic to access the target saphenous vein. The local anaesthetic
should be lignocaine only, as adrenaline would vasoconstrict the target vessel.

•

Access the vein using a Seldinger technique.

•

Insert the introducer sheath and advance to 5cm distal to the saphenous junction
and flush with normal saline.

•

Prime the syringe with n-BCA then connect to the dispenser gun and the
dispensing catheter.

•

Prime the catheter with n-BCA to 3cm short of the tip.

•

Insert the dispensing catheter into the introducer sheath and pull back the sheath
so that the tip of the dispensing catheter is 5cm distal to the junction.

•

Guide and follow the procedure on ultrasound and use the ultrasound probe to
compress the saphenous junction.

•

Inject a 0.1mL aliquot of adhesive into the vein by pulling the trigger of the
dispenser gun and hold for three seconds, then pull back 1cm and deliver another
0.1mL of adhesive for three seconds.

•

Pull the catheter and sheath back by 3cm, maintain proximal compression with the
ultrasound probe and light digital compression for three full minutes before the next
trigger pull.
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•

Maintain proximal compression with the probe and deliver 0.1mL aliquots of
adhesive at 3cm intervals down the vein waiting each time for 30 seconds after
each subsequent trigger pull.

•

Confirm vein closure with ultrasound, then withdraw the delivery systems. For
veins larger than 6mm diameter, consider 0.1mL aliquots at 2cm intervals.

•

Stop 5cm proximal to the access site, withdraw the dispenser catheter into the
introducer sheath and remove the system, then apply pressure until haemostasis
occurs.

5.4.2 VenaBlockTM Procedure
The system uses a 6F PTFE catheter with an atraumatic tip with a laser guiding light that
shines through the skin to allow precise placement of the tip in relation to the saphenous
junction. It also has high echogenicity for ultrasound guidance.
•

Select the access point based on the clinical indications and the treatment plan.

•

Inject local anaesthetic to access the target saphenous vein. The local anaesthetic
should be lignocaine only, as adrenaline would vasoconstrict the target vessel.

•

Gain access using an 18G angio-needle.

•

Insert the short introducer (11cm) into the target vessel and flush with saline then
remove the guidewire.

•

Draw up VenaBlockTM into the provided syringe to a volume of 2mL.

•

Attach the syringe to the dispensing gun, check the catheter laser tip by turning
the switch on.

•

Attach the catheter to the syringe which is already connected to the dispensing
gun then prime the catheter to 3cm short of the tip.
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•

Insert the catheter via the introducer into the target vessel and follow the tip of the
catheter as it approaches the saphenous junction on ultrasound.

•

Place the tip of the catheter at approximately 2.5cm distal to the saphenous
junction.

•

Apply pressure over the saphenous junction cephalad to the catheter with the help
of an assistant and maintain for 10 seconds after the first injection.

•

Use continuous infusion of n-BCA from the 3mL syringe with a slow steady rate of
catheter withdrawal to produce a continuous column of glue. Aim for delivery of
0.06mL/sec with a pull-back rate of 2cm/sec. This equates to 0.3mL of polymer
delivered to a 10cm length of vein.

•

Maintain proximal pressure following the laser beam as the catheter is withdrawn.

•

Confirm venous closure by ultrasound, remove the catheter and apply
compression to the catheter entry site until haemostasis is achieved.

5.5

Technique: Percutaneous Treatment of Tributaries

5.5.1 VenaBlockTM and VeinoffTM
Direct percutaneous administration can be used to treat tributary veins. Venous tributaries
can be dealt with at the same time as treatment of saphenous trunks or at a later date.
Only VenaBlockTM and VeinoffTM are registered by TGA for direct percutaneous injection.
VenaBlockTM has been used to treat saphenous veins less than 3mm diameter, tributaries
located at least 5mm deep to the skin, neovascularization and perforators. Similarly,
VeinoffTM should only be used to treat superficial tributaries at least 5mm deep to the skin.
Care should be taken with the injection of these substances superficially and monitoring
is required to report glue extrusion as observed in gastric cases.
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VeinoffTM can be mixed with 5% dextrose in a ratio of 2:1 (dextrose : VeinoffTM) but the
syringe needs to be shaken to ensure that the mixture is homogenous. The volume
injected at each site is determined by the vein diameter. This technique has been used in
other countries, and to our knowledge it has not been refined or used in Australia or New
Zealand. Withdraw the adhesive into a 1mL syringe and inject with a 22-25-gauge needle.
The adhesive must be injected as expeditiously as possible to avoid hardening within the
syringe.
•

Inject approximately 0.1-0.2mL of adhesive into the target vein at 2-3cm intervals.

•

Apply firm compression after each injection for 60 seconds to prevent palpable
lumps forming in the vein.

•

It is highly recommended not to draw blood back into the hub of the needle as this
will result in casting of the CAC in the syringe and needle, making it virtually
impossible to inject the medical adhesive

•

If injection is performed close to the deep system, ideally it is advisable to deliver
adhesive at least 2cm away from the deep veins where possible.

•

Confirm venous closure by ultrasound after each injection.

5.5.2 VenasealTM
Although designed and approved for use as a catheter-directed procedure only, clinicians
have used VenasealTM by direct percutaneous injection.83 In view of the increased
viscosity of this product compared with other glues, direct percutaneous injection of
VenasealTM is best achieved with a 22-25 gauge needle and a 1-3mL luer lock syringe.
When used via direct percutaneous injection, small aliquots of 0.1-0.2mL per injection site
are recommended and precise dosing is facilitated via the use of a 1mL syringe. Be wary
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that these aliquots may cause palpable lumps if injected in sub-dermal veins close to skin
surface. It is difficult to compress the small occlusive blocks of n-BCA after polymerisation
in the target veins. One way of countering this is to inject a little harder and faster through
a 21 g needle and compress the vein as the injection is performed

5.6

Post-operative Management

5.6.1 Postoperative Course
The postoperative course is usually benign. Most patients experience mild tightness and
discomfort for up to two weeks but not sufficient to limit normal activities. Some patients
develop a moderate to severe inflammatory reaction. Apart from CAC-induced phlebitis
and DTP, inflammation may occur in target veins close to the cutaneous surface where
mast cell degranulation and the inflammatory process may trigger a cutaneous
inflammatory response. It may also be due to phlebitis in untreated tributaries
communicating with the CAC treated veins. Treatment usually requires applying
compression and oral non-steroidal anti-inflammatory drugs (NSAIDS).
5.6.2 Postoperative Instructions
The patient should be mobilised immediately after treatment and should walk regularly
each day for the next week or two. Normal activities can be resumed immediately but
heavy physical activities should be avoided for at least 7-14 days.
An inflammatory reaction over the treated vein may occur comparable to that frequently
seen after ETA. Many patients find comfort from support stockings for a few days after
treatment. Therefore, elastic compression stockings can be worn at the patients’
discretion and based on medical advice to prevent phlebitis especially when large
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adjoining tributaries are present. In addition, Morrison et al. recommend routine use of
NSAIDS to commence a day before the procedure and continued for 5 days. 54
Continuous air or vehicle travel of more than five hours duration is not advised within two
weeks before or after the procedure. If such travel is necessary, then consider the need
for prophylactic anticoagulation to commence immediately prior to travel and continue for
two days after arrival at the destination. 84
5.6.3 Postoperative Ultrasound Examinations
We currently recommend that the treated legs be examined with an ultrasound scan
within 7 days of treatment to exclude VTE.
Early and long-term follow-up to assess ultrasonic success should be arranged at 6-12
weeks and annually afterwards. At each examination, the treated vein should be
assessed for residual patency at any site, the appearance and diameter of the occluded
vein, the upper level of occlusion in relation to the saphenous junction, residual varices
and tributaries, and DVT or deep vein occlusion from the injected glue. Ultrasound
examination should then be followed by a clinical review to assess resolution of
symptoms, control of varices, any complications and patient satisfaction.
Post-operative ultrasound surveillance shows an echogenic material with a strong
shadow artefact in the vein, corresponding with the injected glue with a similar
appearance with serial scans going out to three years. Morrison et al.54 have reported
some of the treated veins to have completely disappeared after five years.
5.6.4 Follow-up Clinical Examination
•

A complete medical history and physical examination should be performed.

•

CEAP classification should be recorded.
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•

Follow-up photographs of lower limbs and other relevant photographs should be
obtained.

5.7 Reporting of Complications
Any complications arising from the use of all CA products should be reported to the ARTG.
The registered title for these products is “Venous Adhesive Occlusion System” and the
ARTG entry number needs to be used in the search engine (Table 4 and 5). In addition,
the ACP has provided a method of reporting of the safety data following endovenous
procedures and including CAC, available from its website.

5.8

Advertising and Business Considerations

While it may be tempting to advertise this new and seemingly attractive treatment option,
be aware that section 133 of the Australian National Law prohibits advertising that:
•

is false, misleading or deceptive or is likely to be so,

•

offers a gift or discount or other inducement to attract a user of the health service
without stating the terms and conditions of the offer,

•

provides a service without stating the terms and conditions of the offer,

•

uses testimonials or purported testimonials,

•

creates an unreasonable expectation of beneficial treatment and/or encourages
the incrimination or unnecessary use of health services.

In New Zealand, Section 58 of the Medicines Act 1981 states that:
•

advertising direct to the consumer for treatment of varicose veins must not mislead
the public, and

•

practitioners must not frontspeak or appear in advertisements for medical clinics.
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These guidelines cover all types of advertising including social media, blogs and
websites. Practitioners should adhere to the published advertising guidelines and ensure
the public is not misled in believing CAC is a ‘miracle’ treatment with no adverse reactions.
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SUMMARY
Scientific literature dealing with CAC is sparse and only limited long term studies on the
biologic effects and the tissue response to n-BCA when used to occlude superficial veins
is available. Current studies lack accurate description of complications and long-term data
on complications is not available. Future studies need to clearly differentiate between the
reported complications of CAC and in particular should differentiate between ICD, ACD,
HTP, STP and GTP.
Technically, CAC provides a simple alternative to surgical stripping and ETA of the
saphenous veins. This treatment should not be offered to patients with a documented
allergy to CA products, acrylates, and in particular commercial preparations of ‘Superglue’, eyelash extension glues and acrylic nails. Other contraindications include
concurrent acute uncontrolled inflammatory, granulomatous or autoimmune disorders.
Care should be exercised in using these products in patients with a history of inflammatory
granulomatous or autoimmune disorders. It is also recommended that phlebologists using
n-BCA keep a record of adverse outcomes and communicate these regularly to
colleagues until a formal reporting register is established.
It is strongly recommended that medical and allied health professionals using CA avoid
direct skin contact with the product to prevent sensitisation.
Finally, this is best practice advice based on relatively sparse current information, to
provide some early structure and safety for the use of this new technology. Future advice
and recommendations will supercede this document when further information becomes
available.

52

ACKNOWLEDGEMENTS
The panel would like to thank Prof. Ken Myers for significant contribution to the initial
drafts of this document. We would like to thank our international colleagues Dr Nick
Morrison (USA) and Prof. Evgeny Shaidakov (Russian Federation) for sharing slides,
papers and personal experience.
We also thank Yunus Cakiroglu from Invamed and Monte Madsen from Medtronics for
providing information regarding their respective products. The ACP would like to thank
Invamed for sponsoring the face-to-face meeting of the panel members.

CONFLICTS OF INTEREST
No relevant conflicts of interests were declared. One author (Stefania Roberts) had
served as a consultant for Medtronic from 2014-2016.

53

REFERENCES

LEGENDS
Table 1
List of abbreviations used in this manuscript.

Table 2
Comparison of physiochemical properties of cyanoacrylate adhesive agents used in the
treatment of peripheral veins. Data obtained from manufacturers (Medtronic and
Invamed). Viscosity values are expressed in cP (centipoise). The viscosity of water is 1
cP at 20 C. The VenaSealTM preparation has the highest while Veinoff TM has the lowest
0

viscosity. VenaSealTM has the slowest while VenaBlockTM has the fastest polymerisation
time.

Table 3
Registration details of VenaSealTM with Australian Therapeutic Goods Administration
(TGA).

Table 4
Registration details of VenaBlockTM with Australian Therapeutic Goods Administration
(TGA).

Table 5
Summary of CAC procedure for peripheral veins complications reported in the literature.
Adapted from Lam et al.72, with recent updates.
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Figure 1
Product appearance in its packaging. Note the colourlessness of VenaSeal TM, while
VenaBlockTM and Histoacryl Blue® have a clear blue colour.
Figure 1A: VenaSealTM
Figure 1B: Left, VenaBlockTM ; Right, VenaBlockTM drawn up in syringe
Figure 1C: Left, Histoacryl Blue® drawn up in syringe; Right, Histoacryl Blue® in tube.

Figure 2
Molecular structure of cyanoacrylate and the polymerisation process. Adapted from
Pollak and White 17

Figure 2A:

Monomeric cyanoacrylate CH =C(CN)−COOR. The R represents an alkyl
2

group.

Figure 2B:

n-butyl-2-cyanoacrylate (n-BCA). The carboxyl ethyl (−COOH−CH −CH )
2

2

group is the antigenic component of the molecule.

Figure 2C: Polymerisation process of cyanoacrylate (CA). Exposure of CA monomers to
an anion, such as the hydroxyl (−OH) group in water initiates the polymerisation process
with bonding of the ethylene units.

Figure 3
Initiation of the polymerisation process of cyanoacrylate molecule with bonding of the
ethylene units.
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Appendix 1
Standard questions submitted to Invamed and Medtronic regarding VenaBlockTM and
VenaSealTM
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Table 1
ABBREVIATIONS
ACD
ACP
APC
ARTG
AVM
CA
CAC
CE
DMSO
ETA
EVLA
EVOH
FDA
GCS
GSV
GTP
HDPE
HTP
ICD
INR
IR
LMWH
MHRA
N-BCA
NSAIDS
NTNT
PMN
PTFE
PE
RFA
SFJ
SNS
SSV
STP
SLE
TA
TGA
UGS
UK
USA
VTE

FULL DESCRIPTION

Allergic Contact Dermatitis
Australasian College of Phlebology
Antigen presenting cells
Australian Register of Therapeutic Goods
arteriovenous malformation
cyanoacrylates
cyanoacrylate adhesive closure
Conformité Européene
dimethyl sulfoxide
endothermal ablation
endovenous laser ablation
ethylene vinyl alcohol
Food and Drug Administration
graduated compression stockings
great saphenous vein
granulomatous-type phlebitis
high density polyethylene
hypersensitivity-type phlebitis
Irritant contact dermatitis
interventional neuro-radiology
interventional radiology
low molecular weight heparin
Medicines and Healthcare Products Regulatory Agency
n-butyl cyanoacrylate
non-steroidal anti-inflammatory drugs
non-thermal non-tumescent
polymorphonuclear
polytetrafluroethylene
pulmonary embolism
radiofrequency ablation
saphenofemoral junction
signature nail systems
small saphenous vein
superficial thrombophlebitis
systemic lupus erythematosus
tumescent anaesthesia
Therapeutic Goods and Administrations
ultrasound guided sclerotherapy
United Kingdom
United States of America
venous thromboembolism
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Table 2
VenaBlockTM
Polymer length

Short chain

Action
Viscosity

Rigidity

VenaSealTM

Medium
chain

Long chain

¶

(alkyl group)

Polymerisation
time

VeinoffTM

Fastest 5 (s)

Medium 15 (s)

†

Slowest
30-180 (s)

Fastest

Slower

Slowest

20 cP

18 cP

>1200 cP

Relatively
firm

Soft and malleable

Soft and flexible

Biodegradability

Permanent
implants.

¶

20-30% larger than Venoblock

†

VeinoffTM with 5% dextrose has a longer polymerisation time of 60 seconds

‡

‡

At 37 C
0
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Table 3

Product

VenaSealTM

Registered Title

Venous adhesive occlusion system

ARTG Entry

194201

ARTG entry for

Medical Device Included Class IIb

Sponsor

Medtronic Australasia Pty Ltd

ARTG Start Date

30/01/2012

Product

Medical Device Class IIb

category
Approval area

Medical Devices

Manufacturer

Sapheon Inc

Manufacturer

951 Aviation Parkway Suite 900, Morrisville, NC, 27560, USA

Address
Intended

Intended for the permanent, complete, endovascular adhesive closure of

purpose

the great saphenous vein (GSV) and associated varicosities in the

treatment of venous reflux disease

Table 4
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Product

VenaBlockTM

Registered Title

Venous adhesive occlusion system

ARTG Entry

283020

ARTG entry for

Medical Device Included Class IIb

Sponsor

Diverse Devices Pty Ltd

ARTG Start Date

29/11/2016

Product

Medical Device Class IIb

category
Approval area

Medical Devices

Manufacturer

Invamed Saglik llac San ve Tic AS

Manufacturer

Anadolu OSB 30 Agustos Cad No 13 Malikoy

Address

Ankara, Turkey

Intended

Intended for the permanent, complete, endovascular adhesive closure of

purpose

the great saphenous vein (GSV) and associated varicosities in the

treatment of venous reflux disease

60

Table 5
Major

Minor

1 Author,
Year
DVT
PE
(no. of
subjects)
Almeida,
2015/2017
0
0
(38)
Proebstle,
2015
0
0
(70)
Morrison
2015
0
0
(108)
Tekin,
2016
0
0
(62)
Bozkurt,
2016
0
0
(310)
Gibson,
2016
0
0
(61)
Kullori,
5%
2016,
unspecified
(108)
Chan,
2017
0
0
(108)
Koramaz,
2017
0
0
(150)
Park,
2017
0
0
(34)
st

Yasim,
2017
(180)

0

0

Phlebitis

SV
T

Minor
allergic
reaction

Injection site
complication
s

Other

Pigme
ntation

Paraes
thesia

Glue
migrati
on

16%

3
%

NR

28.3%

NR

2.6%*

NR

21.1%

11.4%

NR

NR

1% infection

NR

NR

0

21%

20%

4%

NR

1%
Infection

3%

NR

3%

0

3.2%
thrombo
phlebitis

NR

NR

NR

1.6% h
aemato
ma

NR

NR

0

4.5%

NR

NR

14.3%
ecchymosis

NR

1.3%

0

0

16.4%

NR

1.6%

1.6%
Local site
reaction

1.6%

NR

NR

1.6%

^

ƪ

±

¶

†

Unspecified. 20.4% mild, 5.6% moderate

4%

2.1%

NR

NR

‡

4%

NR

1% infection

NR

NR

1%

NR

NR

NR

NR

0

0

NR

NR

8% ᵞ

NR

NR

11.8%

0

0

NR

0
haematoma
/ecchymosi
s

NR

NR

NR

NR

NR

‡

70%
Burning
0
0
1.1%
NR
NR
0
0
sensati
on
DVT, deep vein thrombosis; NR, not reported; PE, pulmonary embolism; SVT, superficial vein
thrombosis. ^ Resolved with non-steroidal anti-inflammatory drugs. 10.5% inflammation, 2.6%
vesicles, 2.6% ulcer, 2.6% swelling, 2.6% skin irritation, 1% infection. * persistent after one-year
follow-up. 1% Light-headedness post procedure 2% stocking irritation. Total body hives for 1
week resolved with antihistamines and short oral steroids. intraoperative Nausea/light
Yavuz,
2018
(538)

5%
ecchymosis

±

ƪ

¶

†
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3.5%

0

headedness.‡ resolved.ᵞ abnormal skin reaction: erythema, itching, pain, oedema and tenderness
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Figures
Figure 1
A

B

C
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Figure 2
Figure 2A

Figure 2B

Figure 2C
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Appendix 1
1. The manufacture and approval timeline of the product around the world.
2. The official registration document summary as well for each of the approvals e.g. the
TGA/FDA/CE product summary
3. Toxicology information on the product
4. Information on all the studies done on the product- observational or randomised trials
(human/animal/in vitro)
5. Information on the histopathology of the healing process of the injected vein. Is there
a granuloma formation with a foreign body reaction? Please also provide the histology
slides if available.
6. Composition, viscosity, polymerisation, pliability, tensile strength and adhesion
strength of the glue
7. Biodegradability of the glue
8. Why is the glue blue?
9. Does it use a PTFE catheter? If not, what catheter does it use?
10. Information on Dr Raabe, Sapheon doctor who invented the glue.
11. Relationship between temperature and viscosity of the glue and the mechanism
behind it.
12. Is there any cross reactivity with the adhesive used in dressings?
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